Alkem Labs' shares fall on row over fudging trial data

MUMBAI (Reuters) - Shares in Alkem Laboratories Ltd fell as much as 8 percent on Monday after the company confirmed it was in talks with German authorities who had accused it of fudging data in some clinical trials.

Reuters reported on Friday that German authorities had accused the company of manipulating heart readings of patients in some trials for the antibiotic cefuroxime and the brain disorder drug rulizole, following an inspection of Alkem's plant in Taloja in western India in March 2015.

The European Medicines Agency (EMA) is investigating the medicines after Germany reported its findings to the EMA and urged it to take action in a report that was posted on the EMA website.

Alkem said in a statement on Saturday that the company had responded to the German authorities with a "robust remediation plan" and would also submit "suitable clarification" to the EMA.

Similar findings by European regulators concerning manipulation of electrocardiogram data at two other Indian firms, GVK Biosciences and Quest Lifesciences, led to the recall of nearly 700 medicines last year.

Alkem said the inspection concerned studies conducted by the company between March 2013 and March 2015 on two products, one of which is selling, while the other is yet to reach the market. It did not name the products. (http://bit.ly/1Te0bTs)

It also said it had changed staff, upgraded equipment and improved its quality assurance systems at the Taloja plant since Germany's inspection.

Alkem, among the fastest-growing drugmakers in India, said sales from Europe made up less than 1 percent of its total revenue in the nine months to December 2015.

Still, the company's shares were down 5 percent at 0459 GMT on Monday, after falling as much as 8 percent earlier in the day - their lowest since Feb. 29. The company debuted on the Indian stock exchanges in December.

(Reporting by Zeba Siddiqui in Mumbai; Editing by Richard Pullin)